CompletedNCT00253149

A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of manic episodes Associated With Bipolarity

This study evaluated the safety and effectiveness of risperidone for people with bipolarity.

Medication studyAges 18–65

The study in practice

Understand this study

This study evaluated the safety and effectiveness of risperidone for people with bipolarity.

Listed age limits: 18 years to 65 years.

Study clarity

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 158
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT00253149
Official title: Show the full official title
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder

Completed

Locations not listed

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of risperidone for people with bipolarity.

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including risperidone.

Who was this study for?

Listed age limits: 18 years to 65 years.